MX2020011269A - Dispositivo de administración transdérmica de tetrabenazina. - Google Patents

Dispositivo de administración transdérmica de tetrabenazina.

Info

Publication number
MX2020011269A
MX2020011269A MX2020011269A MX2020011269A MX2020011269A MX 2020011269 A MX2020011269 A MX 2020011269A MX 2020011269 A MX2020011269 A MX 2020011269A MX 2020011269 A MX2020011269 A MX 2020011269A MX 2020011269 A MX2020011269 A MX 2020011269A
Authority
MX
Mexico
Prior art keywords
tetrabenazine
transdermal delivery
delivery device
adhesive
combination
Prior art date
Application number
MX2020011269A
Other languages
English (en)
Inventor
Hock S Tan
Suresh Borsadia
Kalpana Patel
Original Assignee
Shinkei Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shinkei Therapeutics Llc filed Critical Shinkei Therapeutics Llc
Publication of MX2020011269A publication Critical patent/MX2020011269A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

En la presente se proporcionan dispositivos de administración transdérmica que comprenden tetrabenazina, una tetrabenazina deuterada, o una combinación de estas. En la presente también se proporcionan composiciones farmacéuticas, tales como composiciones adhesivas que comprenden tetrabenazina, una tetrabenazina deuterada, o una combinación de estas, por ejemplo, dispersas de forma homogénea en un adhesivo, tal como un adhesivo sensible a la presión. En la presente se proporcionan además métodos para usar dispositivos de administración transdérmica o composiciones farmacéuticas, por ejemplo, para tratar un trastorno de movimiento hipercinético.
MX2020011269A 2018-04-25 2019-04-24 Dispositivo de administración transdérmica de tetrabenazina. MX2020011269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662456P 2018-04-25 2018-04-25
PCT/US2019/028900 WO2019209940A1 (en) 2018-04-25 2019-04-24 Tetrabenazine transdermal delivery device

Publications (1)

Publication Number Publication Date
MX2020011269A true MX2020011269A (es) 2020-12-11

Family

ID=68295781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011269A MX2020011269A (es) 2018-04-25 2019-04-24 Dispositivo de administración transdérmica de tetrabenazina.

Country Status (12)

Country Link
US (1) US20210128490A1 (es)
EP (1) EP3784237B1 (es)
JP (1) JP7386544B2 (es)
KR (1) KR20210005623A (es)
CN (1) CN112165942B (es)
AU (1) AU2019261403A1 (es)
BR (1) BR112020021700A2 (es)
CA (1) CA3097189A1 (es)
DK (1) DK3784237T3 (es)
MX (1) MX2020011269A (es)
WO (1) WO2019209940A1 (es)
ZA (1) ZA202006415B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021081022A1 (en) * 2019-10-22 2021-04-29 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
TW202203921A (zh) * 2020-03-30 2022-02-01 美商神經治療有限責任公司 右美沙芬之經皮輸送技術

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313723A (ja) * 1987-06-16 1988-12-21 Nitto Electric Ind Co Ltd 外用貼付剤
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP4988080B2 (ja) * 1997-09-05 2012-08-01 日東電工株式会社 経皮吸収型製剤
DE69833000T2 (de) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
AU2001292781A1 (en) * 2000-09-19 2002-04-02 National Starch And Chemical Investment Holding Corporation Acryl adhesive useful in transdermal drug delivery systems
MX2007004315A (es) * 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
BRPI0913457B8 (pt) * 2008-09-18 2021-08-31 Auspex Pharmaceutical Inc Composto e composição farmacêutica
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
CA2869145A1 (en) * 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
PL2872126T3 (pl) * 2012-07-16 2018-06-29 Grünenthal GmbH Plaster farmaceutyczny do przezskórnego podawania tapentadolu
US9682068B2 (en) * 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
CN105377245B (zh) * 2013-06-04 2018-07-17 Lts勒曼治疗系统股份公司 透皮递送系统
KR20240011255A (ko) * 2014-05-06 2024-01-25 뉴로크린 바이오사이언시즈 인코퍼레이티드 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
US11191734B2 (en) * 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system

Also Published As

Publication number Publication date
US20210128490A1 (en) 2021-05-06
AU2019261403A1 (en) 2020-11-12
CN112165942A (zh) 2021-01-01
WO2019209940A1 (en) 2019-10-31
ZA202006415B (en) 2024-04-24
BR112020021700A2 (pt) 2021-01-26
EP3784237A1 (en) 2021-03-03
EP3784237B1 (en) 2023-11-01
TW202014187A (zh) 2020-04-16
JP7386544B2 (ja) 2023-11-27
DK3784237T3 (da) 2024-01-08
CN112165942B (zh) 2024-04-12
JP2021522240A (ja) 2021-08-30
EP3784237A4 (en) 2022-02-16
CA3097189A1 (en) 2019-10-31
KR20210005623A (ko) 2021-01-14

Similar Documents

Publication Publication Date Title
MX2022010168A (es) Moduladores de calpainas y usos terapeuticos de los mismos.
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
MX2019005833A (es) Administracion transdermica de agentes grandes.
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
MX2017003623A (es) Parche de opipramol.
PH12018502738A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
BR112018008103A2 (pt) análogos de celastrol
ZA202006415B (en) Tetrabenazine transdermal delivery device
DK3706841T3 (da) Kanyleskjoldsfjerner og medikamentafgivelsesindretning, der omfatter kanyleskjoldsfjerneren
MA40473A (fr) Dispositifs d'administration de médicaments à base d'une silicone catalysée par du platine, et leurs procédés d'utilisation
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2020011371A (es) Nuevos dispositivos medicos, vehiculos de suministro y fabricacion de los mismos.
MX2021006102A (es) Suministro mejorado de agentes grandes.
CL2016001104A1 (es) Preparación farmacéutica y método de su producción y uso.
IL273735A (en) A device for transdermal delivery of dextromethorphan
MX2018007231A (es) Una composicion antimicrobiana.
SA517381471B1 (ar) وحدة عقار- جهاز تحتوي على كيناجولايد
EP3766536A4 (en) MEDICATION DELIVERY DEVICE, APPARATUS AND SET
PH12017501563A1 (en) Oligomeric/polymeric silicone fluids for use in transdermal drug delivery systems
MX2022004827A (es) Dispositivo de administracion transdermica de tetrabenazina.
TW201613952A (en) Cdca1-derived peptide and vaccine containing same
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
CL2016003271A1 (es) Métodos para tratar infecciones
MX2018009739A (es) La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas.
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.